Abstract. Adult neurogenesis in the subventricular zone (SVZ), as well as in the subgranular zone contributes to brain maintenance and regeneration. In the adult brain, dopamine (DA) can regulate the endogenous neural stem cells within these two regions, while a DA deficit may affect neurogenesis. Notably, the factors that regulate in vivo neurogenesis in these subregions have not yet been fully characterized, particularly following DA depletion. In this study, we performed RNA sequencing to investigate transcriptomic changes in the SVZ and dentate gyrus (DG) of mice in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This analysis identified differentially expressed genes which were involved in the regulation of transcription, immune response, extracellular region, cell junction and myelination. These genes partially displayed different temporal profiles of expression, some of which may participate in the metabolic switch related to neurogenesis. Additionally, the mitogen-activated protein kinase (MAPK) signaling pathway was shown to be positively regulated in the SVZ, while it was negatively affected in the DG following MPTP administration. Overall, our findings indicate that exposure to MPTP may exert different effects on transcriptome profiling between the SVZ and DG.

Introduction
Active neurogenesis occurs throughout life in the subventricular zone (SVZ) of the lateral ventricle, as well as in the subgranular zone (SGZ) of the dentate gyrus (DG) (1). Currently, scientific interest in endogenous repair has mostly focused on these two regions that harbor multipotent neural stem cells (NSCs), which can give rise to interneurons and contribute to neural plasticity (1,2). However, neurogenesis profiling that is activated or inhibited has been a subject of heated debate. Several findings have provided evidence that DA denervation reduces cell proliferation, differentiation and migration in the SVZ and SGZ in individuals with PD, as well as in mice administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (2,5), while others have emphasized that the proliferative capacity of the SVZ and SGZ is not diminished (4,5) or even increased (2,6,7) in the parkinsonian brain. Notably, there are several essential signaling pathways regulating proliferation, differentiation and migration, as well as the survival of neural precursor cells (NPCs), and their integration into the neuronal circuitry network in the adult brain, e.g., Notch, Sonic hedgehog (Shh), mitogen-activated protein kinase (MAPK) and Eph:ephrin signaling pathways (5,8-10). In addition to signaling transduction pathways, metabolic factors serve as important modulators of neurogenesis (9). The alterations in these modulators, such as growth factors during glycolysis, oxidative phosphorylation, lipogenesis and protein synthesis may be associated with the development of neurodegenerative diseases (10-13).
In our study, adult mice were exposed to MPTP. We then carried out transcriptomic analysis on the tissues of the SVZ and DG using RNA sequencing (RNA-Seq) technology, and observed significantly deregulated gene expression following the MPTP administration. Bioinformatics analysis using the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) databases was applied to interpret the related function of the differentially expressed genes. Future studies using single-cell sequencing are required to further investigate the molecular targets for neuroplasticity in the SVZ and SGZ.

Materials and methods

MPTP administration and behavioral tests. All animal experiments were performed in accordance with the guidelines on the Care of Laboratory Animals, and have been approved by the Ethics Committee of Peking Union Medical College Hospital, Beijing, China. A total of 52 adult C57BL/6J female mice (10 weeks old) weighing approximately 25 g were randomly assigned to 2 groups: i) MPTP-exposed group (n=29) and ii) saline-treated group (n=23). As previously described, MPTP hydrochloride (20 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) in saline was injected intraperitoneally and handled in accordance with the published guidelines (14,15). The control mice received intraperitoneal injection of an equal volume of saline. The rotarod test was performed on day 21 after the MPTP injection. All mice were pre-trained approximately 1 week before the tests. One day prior to MPTP administration, the baseline was obtained, and the test series then began at a speed of 26 rpm. Each animal received 2 trials with a rest interval of 5-10 min, and the latencies to fall off the rod within 180 sec were recorded and averaged. For the pole test, mice were placed head upwards on the top of one upright pole approximate 30 cm long and 8 mm in diameter. Once laid upon the top, mice oriented themselves downwards and descended to the ground. Animals also received training that consisted of 3 consecutive trials of each session. After establishing the baseline, each animal experienced 2 trials and the time to descend was recorded.

Immunostaining and immunoelectron microscopy. As previously described (14,16), 21 days following exposure to MPTP, under deep anesthesia, the animals were sacrificed. Immunoperoxidase staining for tyrosine hydroxylase (TH) (1:800; #AB152; Vector Laboratories, Burlingame, CA, USA) was performed. Briefly, the mice were perfused intracardially with 3,3’-diaminobenzidine (DAB). Finally, the sections were dehydrated through a graded series of ethanol, cleared in xylene, coverslipped, and captured on a Nikon Eclipse 90i microscope (Nikon, Tokyo, Japan). Analysis was performed using the Stereo Investigator (MBF Bioscience Inc., Williston, VT, USA) to quantify TH-positive cells in the SN (14).

For direct electron microscopy, the mice were deeply anesthetized and sacrificed by intracardiac perfusion with 2% glutaraldehyde. Anatomically matched coronal sections of the SN and striatum were removed from each mouse and further fixed overnight in 2% glutaraldehyde at 4°C before embedding for electron microscopy. The tissues were then washed in 0.1 M sodium cacodylate buffer (pH 7.4), post-fixed with 2% osmium tetroxide for 30 min, quickly dehydrated through graded ethanol solutions. The brain regions of interest (SN and striatum) were then cut out from tissues identically by the same individual, and covered with fresh Epon. The resulting blocks containing the regions of interest were then trimmed, and viewed on a JEOL JEM-1400Plus transmission electron microscope (JEOL, Ltd., Tokyo, Japan).

Messenger RNA (mRNA) sequencing. Total RNA was extracted from the tissues of the SVZ and DG, and RNA integrity was examined using a NanoDrop 2000/2000c (Thermo Fisher Scientific Inc., Waltham, MA, USA). The RNA library was constructed using TruSeq® RNA LT Sample Prep kit v2 (Illumina Inc., San Diego, CA, USA) according to the manufacturer’s instructions. Briefly, after poly(A)-based mRNA enrichment and RNA fragmentation, first-strand complementary DNA (cDNA) was synthesized using the First Strand Master Mix and SuperScript II, followed by second-strand cDNA synthesis using the Second Strand Master Mix. Double-stranded cDNA was end repaired, and then 3’ ends were adenyalted and the illumina adaptors were ligated. The ligation product was amplified with 15 cycles of polymerase chain reaction. After measures of yield and fragment length distribution, libraries were sequenced using Truseq SBS kit v3-HS, and were generated on the HiSeq 2500 sequencing system (both from Illumina Inc.). Each sequencing library generated minimally 20 million uniquely mapping reads. Images from the instrument were processed using the manufacturer’s software to generate FASTQ sequence files.

Statistical analysis. The data from the behavioral tests and immunostaining are presented as the means ± SEM and analyzed using GraphPad Prism 6.0 software (GraphPad Software, San Diego, CA, USA) for Mac OS X. The difference between 2 groups was analyzed using a two-tailed Student’s t-test, while two-way ANOVA followed by Tukey’s post-hoc analysis were conducted for multiple comparisons between 2 or more groups. A p-value <0.05 was defined as a threshold for statistical significance.

To characterize the transcriptomic profiles, RNA-Seq was performed. Raw reads were trimmed the adaptor sequences with trim Galore. Sequencing reads were mapped to the mouse genome using TopHat 2.1.0. Cufflinks was used to calculate the gene expression values represented as fragments per kilobase per million mapped reads (FPKM). The differential gene
expression analysis of RNA-Seq data was performed using Cuffdiff (17). The differential expression genes were filtered with FPKM >1, q-value <0.05 and log2 fold change >1 or <1, and clustered using Gene Cluster 3.0. In addition, GO and KEGG analysis were conducted using the DAVID bioinformatics database. WEGO was used to plot the GO annotation results. Expression distribution and scatter plots were generated with CummeRbund package in R (18).

Results

MPTP-induced parkinsonism and pathological changes in mice. The rotarod and pole tests were compared between mice administered MPTP and animals receiving saline. No significant difference in behavioral performance was observed prior to MPTP. However, 21 days following exposure to MPTP, a statistically significant deterioration in locomotor activity was observed in the mice given the neurotoxin compared to the saline-treated controls. The mice with PD remained on the rotarod for significantly shorter period of time than the control animals (p<0.05; Fig. 1A). For the pole test, the mice intoxicated with MPTP took a significantly longer time to complete the test (p<0.05; Fig. 1B).

We stereologically counted the number of dopaminergic neurons in the SN stained for TH. When compared with the saline-injected control (Fig. 1C), there was a marked reduction in TH immunoreactivity in the mice administered MPTP (Fig. 1D). The MPTP-exposed mice had an average of only 3,803.29±423.96 dopaminergic neurons in the SN compared with the saline-infused animals which had 14,373.53±1289.03 cells expressing TH (p<0.05; Fig. 1E).

Furthermore, we observed the ultrastructure of neurons in the SN and neurites in the striatum. Striking changes did not occur in the saline group (Fig. 2A and B). In the MPTP-exposed mice, the plasma membrane of dying neurons appeared ruptured, and the perinuclear cytoplasm was severely dilated, including the endoplasmic reticulum (ER) (arrows in Fig. 2C). In addition, there were numerous enlarged dystrophic myelinated axons (asterisks in Fig. 2D) swelled, containing mitochondria with varying degrees of degeneration in the striatum of the mice administered MPTP. Notably, one greatly enlarged mitochondrion grossly deformed into a ring-shaped structure (arrow in Fig. 2E), while another one had prominently residual cristae (black arrowheads in Fig. 2F).

Differential expression of genes in the SVZ and DG of mice following exposure to MPTP. To characterize the transcriptomic profiles in mice at 4 days and 3 weeks after the MPTP administration, RNA-Seq was performed. In the SVZ, we found 106 genes significantly deregulated
774 BAO et al: TRANSCRIPTOME PROFILING OF THE SVZ AND DG IN MICE WITH PD

At different time points: 65 were upregulated and 41 were downregulated (q-value <0.05 compared with the normal groups; Fig. 3A). In the DG, the expression levels of a total of 98 genes were significantly modulated: 43 were upregulated, and 55 were downregulated (q-value <0.05 compared with the normal groups; Fig. 3B). We identified two different temporal profiles of gene expression in the SVZ (Fig. 4A): i) cluster A, genes with long-lasting upregulation [from day 4 to week 3, e.g., pyruvate dehydrogenase kinase, isozyme 4 (Pdk4) and G protein-coupled receptor 17 (Gpr17)]; and ii) cluster B, genes with a marked but transient decrease and further oppositely regulated [e.g., nuclear receptor subfamily 4, group A, member 3 (Nr4a3), Fos-like antigen 2 (Fosl2), early growth response 2 (Egr2), Egr4, and solute carrier family 17 (vesicular glutamate transporter), member 7 (Slc17a7)].

Biological functions and pathway analysis of gene expression changes in the SVZ and DG. To interpret biological functions that may be altered by differential gene expression after MPTP administration, we performed GO analysis using the DAVID bioinformatics database. In the SVZ of the day 4 group, some of the biological functions were downregulated, including transcription factor activity and the transmission of nerve impulse, while the significantly enriched GO term associated with MPTP-induced changes was immune response (Fig. 4B). The increased expression of genes included in immune response indicated that this function was upregulated in the SVZ at the early stage. However, we found a significant enrichment in transcription factor activity, the transmission of nerve impulse and myelination, which were declining at day 4 but presented an opposing direction of changes 3 weeks following exposure (Fig. 5A; Table I). Additionally, other functions were observed with significant downregulation, such as cell adhesion (Fig. 5A). In the DG, a number of biological functions with considerable activation were found (Fig. 5B; Table II), including cell junction,
synapse and fatty acid transport. Notably, the downregulation of the functions, such as transcription activator activity, MAPK phosphatase activity, extracellular region and positive regulation of transcription, suggested a potential negative effect following exposure to MPTP (Fig. 5B).

KEGG pathway analysis was then used to reveal diverse functional entities involved in inter- as well as intra-cellular signaling cascades. Genes involved in the MAPK pathway [e.g., FBJ murine osteosarcoma viral oncogene homolog (Fos), and nuclear receptor subfamily 4, group A, member 1 (Nr4a1)], were significantly upregulated in the SVZ 3 weeks after the MPTP administration, suggesting active signaling in this subregion (Fig. 6). In the DG, we represented significantly downregulated genes in a model of the MAPK pathway. Surprisingly, the molecular signature in response to MPTP resulted in a negative effect upon the cascade (Fig. 7). In addition to the downregulation of transcription factors (Fos and Nr4a1), a marked decrease of dual-phosphatases mRNA [dual specificity phosphatase 1 (Dusp1) and Dusp6] was observed.

**Discussion**

In this study, using a transcriptomic approach and taking into account the time course of the effects, we identified gene expression signature in the SVZ, as well as in the DG induced by an intraperitoneal injection of MPTP. Our results demonstrated that the expression of 106 genes in the SVZ and 98 genes in the DG were modulated in the mice with PD. Immune response, transcription factor activity, transmission of nerve impulse, myelination and cell adhesion in the SVZ, and cell junction, fatty acid transport, extracellular region, and positive regulation of transcription in the DG were biological functions specifically enriched in our deregulated gene list. Overall, our data indicated that exposure to MPTP regulated MAPK signaling cascades through changes in transcription factors, as well as MAPK phosphatases.

**Genes related to neurogenesis in the SVZ.** Based on the temporal effects, the expression profiles of more significantly altered...
genes in the SVZ were divided into two clusters. Cluster A was composed of genes with long-lasting upregulation (e.g., Pdk4 and Gpr17). Pdk4 encodes pyruvate dehydrogenase kinase that inactivates pyruvate dehydrogenase complex in the mitochondria (19), shunting the oxidative phosphorylation of glucose to a glycolytic pathway, particularly after MPTP-induced neurodegeneration (20). Our results revealed that the MPTP-mediated increase in Pdk4 mRNA expression was sustained in the SVZ, indicating a metabolic switch to maintain energy demands. A recent study suggested that the selective activation of Gpr17 promoted neuronal differentiation and neurite elongation (21). In addition, Gpr17 can activate the intracellular phosphorylation of both extracellular signal-regulated kinase (ERK) and p38 cascades (21), which have been identified as members of the MAPK signaling pathway involved in cell proliferation, differentiation and survival (8,9). Likewise, we also identified that Gpr17 exhibits persistent upregulation, which may indicate the active signaling in the SVZ.

Cluster B consisted of genes with a marked decrease at the early stage, but further overrepresented 3 weeks after MPTP exposure. Of note, this cluster included several immediate-early genes (IEGs) (e.g., Nr4a3, Fosl2, Egr2 and Egr4) induced by multiple stressors (22-24). It is well known that DA serves as a regulatory molecule in the SVZ based on the localization of dopaminergic projections along and within this region (25,26). More recent studies on dopaminergic neurons have indicated that haloperidol rapidly induces Nr4a3 in the ventral tegmental area (VTA), and this is accompanied by the induction of TH and the DA transporter-mRNA (27). When genes were ranked by fold change in our study, Nr4a3 was at the top of the list.
of genes, in agreement with previous studies showing that the induction of \textit{Nr4a3} was associated with repeated L-DOPA administration that led to motor improvement (22). The sum of the therapeutic effects indicated that IEGs, such as \textit{Nr4a3}, can be regarded as a hallmark of recovery in the DA-depleted brain. Although the most enriched GO term was immune response at the early stage, in our study, the expression profiles of IEGs (\textit{Nr4a3}, \textit{Egr2}, and \textit{Egr4}) in the SVZ demonstrated that dysfunctional dopaminergic innervation may be partially rescued. In terms of temporal dynamics, some functions referring to the genes we discussed before were also negatively impacted by MPTP at the early stage and further returned to the normal state, including transcription factor activity (\textit{Fos}, \textit{Fosl2}, \textit{Fosb}, \textit{FBJ osteosarcoma viral oncogene homolog B (Fosb)}, \textit{Nr4a1}, \textit{Nr4a3}, and \textit{Egr2}), transmission of nerve impulse (\textit{Slc17a7} and \textit{Egr2}) and myelination (\textit{Egr2}). Firstly, the upregulation of transcription factors (\textit{Fos}, \textit{Fosl2}, and \textit{Fosb}) may influence the expression of various genes involved in cell proliferation and differentiation after extracellular stimuli. Particularly, \textit{Fos} is currently used as a marker of neuronal activity and has been associated with a number of neural responses to acute stimuli expression. A decrease in the level of \textit{Fos} was observed in age-related degeneration, as well as impaired brain development (28). Llorens-Bobadilla \textit{et al} found that the active state of NSCs in the SVZ was associated with the expression of IEGs including \textit{Fos} (10). Moreover, other IEGs such as \textit{Nr4a1}

\begin{table}[h]
\centering
\begin{tabular}{|l|l|l|l|l|}
\hline
Accession no. & Gene symbol & Gene name & FC & q-value \\
\hline
\hline
\multicolumn{4}{|l|}{Genes related with molecular function} \\
\hline
GOTERM\_MF\_FAT transcription factor activity, 8 genes, p-value 7.76E-3 \\
\hline
NM\_010234 & \textit{Fos} & FBJ osteosarcoma oncogene & 1.30 & 0.011 \\
NM\_001077364 & \textit{Tsc22d3} & TSC22 domain family, member 3 & 1.19 & 0.011 \\
NM\_010118 & \textit{Egr2} & Early growth response 2 & 1.69 & 0.011 \\
NM\_008037 & \textit{Fosl2} & Fos-like antigen 2 & 3.06 & 0.011 \\
NM\_001110850 & \textit{Crem} & cAMP responsive element modulator & 1.06 & 0.040 \\
NM\_010444 & \textit{Nr4a1} & Nuclear receptor subfamily 4, group A, member 1 & 1.68 & 0.011 \\
NM\_001307989 & \textit{Nr4a3} & Nuclear receptor subfamily 4, group A, member 3 & 3.60 & 0.011 \\
NM\_008036 & \textit{Fosb} & FBJ osteosarcoma oncogene B & 1.14 & 0.011 \\
\hline
\textbf{Genes related with biological process} \\
GOTERM\_BP\_FAT transmission of nerve impulse, 5 genes, p-value 0.033 \\
\hline
NM\_182993 & \textit{Slc17a7} & Solute carrier family 17, member 7 & 2.52 & 0.011 \\
NM\_007657 & \textit{Cd9} & CD9 antigen & 2.06 & 0.011 \\
NM\_010118 & \textit{Egr2} & Early growth response 2 & 1.69 & 0.011 \\
NM\_001205075 & \textit{Pnoc} & Prepronociceptin & 1.44 & 0.019 \\
NM\_011674 & \textit{Ugta8} & UDP galactosyltransferase 8A & 1.17 & 0.011 \\
\hline
GOTERM\_BP\_FAT regulation of membrane potential, 4 genes, p-value 0.026 \\
\hline
NM\_007657 & \textit{Cd9} & CD9 antigen & 2.06 & 0.011 \\
NM\_010118 & \textit{Egr2} & Early growth response 2 & 1.69 & 0.011 \\
NM\_011674 & \textit{Ugta8} & UDP galactosyltransferase 8A & 1.17 & 0.011 \\
NM\_00112813 & \textit{Cacna1g} & Calcium channel, voltage-dependent, T type, \(\alpha 1G\) subunit & -1.05 & 0.019 \\
\hline
GOTERM\_BP\_FAT axon ensheathment, 3 genes, p-value 0.019 \\
\hline
NM\_007657 & \textit{Cd9} & CD9 antigen & 2.06 & 0.011 \\
NM\_010118 & \textit{Egr2} & Early growth response 2 & 1.69 & 0.011 \\
NM\_011674 & \textit{Ugta8} & UDP galactosyltransferase 8A & 1.17 & 0.011 \\
\hline
GOTERM\_BP\_FAT myelination, 3 genes, p-value 0.017 \\
\hline
NM\_007657 & \textit{Cd9} & CD9 antigen & 2.06 & 0.011 \\
NM\_010118 & \textit{Egr2} & Early growth response 2 & 1.69 & 0.011 \\
NM\_011674 & \textit{Ugta8} & UDP galactosyltransferase 8A & 1.17 & 0.011 \\
\hline
\end{tabular}
\caption{Selected genes differentially expressed in the SVZ of mice 3 weeks after MPTP exposure.}
\end{table}
Table II. Selected genes differentially expressed in the DG of mice 3 weeks after MPTP exposure.

| Accession no. | Gene symbol | Gene name | FC  | q-value |
|---------------|-------------|-----------|-----|---------|
| **Genes related with molecular function** |
| **GOTERM_MF_FAT transcription activator activity, 7 genes, p-value 2.22E-3** |
| NM_007913 | Egfl | Early growth response 1 | -1.55 | 0.006 |
| NM_027225 | Hdac4 | Histone deacetylase 4 | 1.16 | 0.010 |
| NM_010444 | Nr4a1 | Nuclear receptor subfamily 4, group A, member 1 | -1.77 | 0.006 |
| NM_019740 | FoxO3 | Forkhead box O3 | 1.20 | 0.006 |
| NM_001307989 | Nr4a3 | Nuclear receptor subfamily 4, group A, member 3 | 1.01 | 0.010 |
| NM_0111141 | Pou3f1 | POU domain, class 3, transcription factor 1 | -3.65 | 0.006 |
| NM_153553 | Npas4 | Neuronal PAS domain protein 4 | -2.04 | 0.006 |
| **Genes related with cellular component** |
| **GOTERM_CC_FAT synapse, 7 genes, p-value 4.14E-3** |
| NM_027225 | Hdac4 | Histone deacetylase 4 | 1.16 | 0.010 |
| NM_001276684 | Arc | Activity regulated cytoskeletal-associated protein | -1.67 | 0.006 |
| NM_008067 | Gabra3 | Gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 | -1.12 | 0.006 |
| NM_008069 | Gabrb1 | Gamma-aminobutyric acid (GABA) A receptor, subunit beta 1 | 1.02 | 0.006 |
| NM_008170 | Grin2a | Glutamate receptor, ionotropic, NMDA2A (ε1) | 1.02 | 0.006 |
| NM_009229 | Sntb2 | Syntrophin, basic 2 | 1.18 | 0.006 |
| NM_029210 | Sv2c | Synaptic vesicle glycoprotein 2c | 1.46 | 0.006 |
| **GOTERM_CC_FAT extracellular region, 19 genes, p-value 6.37E-4** |
| NM_001313969 | Vip | Vasoactive intestinal polypeptide | -1.06 | 0.033 |
| NM_001159487 | Rbp4 | Retinol binding protein 4, plasma | -2.16 | 0.027 |
| NM_008940 | Klk8 | Kallikrein related-peptidase 8 | -1.33 | 0.020 |
| NM_198408 | Cbrbp | Corticotropin releasing hormone binding protein | -1.99 | 0.006 |
| NM_177059 | Fstl4 | Follistatin-like 4 | 1.06 | 0.043 |
| NM_008597 | Mgp | Matrix Gla protein | -1.43 | 0.022 |
| NM_001122736 | Igf2 | Insulin-like growth factor 2 | -2.00 | 0.006 |
| NM_001190451 | Dcn | Decorin | -1.77 | 0.006 |
| NM_183136 | Spink8 | Serine peptidase inhibitor, Kazal type 8 | -2.29 | 0.006 |
| NM_009177 | St3gal1 | ST3 beta-galactoside α-2,3-sialyltransferase 1 | 1.02 | 0.006 |
| NM_010930 | Nov | Nephroblastoma overexpressed gene | -4.57 | 0.006 |
| NM_008963 | Ptgsd | Prostaglandin D2 synthase (brain) | -1.73 | 0.006 |
| NM_001301353 | Apod | Apolipoprotein D | -1.31 | 0.006 |
| NM_022312 | Tnr | Tenascin-R | 1.02 | 0.006 |
| NM_030890 | Prrt1 | Proline-rich transmembrane protein 1 | 1.01 | 0.006 |
| NM_139298 | Wnt9a | Wingless-type MMTV integration site family, member 9A | -1.06 | 0.006 |
| NM_007729 | Coll1a1 | Collagen, type XI, α1 | -1.08 | 0.020 |
| NM_010517 | Igfbp4 | Insulin-like growth factor binding protein 4 | -1.22 | 0.006 |
| NM_012045 | Pla2g2f | Phospholipase A2, group IIF | 1.28 | 0.006 |
| **GOTERM_CC_FAT cell junction, 8 genes, p-value 7.00E-3** |
| NM_001276684 | Arc | Activity regulated cytoskeletal-associated protein | -1.67 | 0.006 |
| NM_021424 | Prrl1 | Poliovirus receptor-related 1 | 1.18 | 0.006 |
| NM_008067 | Gabra3 | Gamma-aminobutyric acid (GABA) A receptor, subunit alpha 3 | -1.12 | 0.006 |
| NM_008069 | Gabrb1 | Gamma-aminobutyric acid (GABA) A receptor, subunit beta 1 | 1.02 | 0.006 |
| NM_008170 | Grin2a | Glutamate receptor, ionotropic, NMDA2A (ε1) | 1.02 | 0.006 |
| NM_009229 | Sntb2 | Syntrophin, basic 2 | 1.18 | 0.006 |
| NM_001083119 | Pprru | Protein tyrosine phosphatase, receptor type, U | -1.31 | 0.006 |
| NM_029210 | Sv2c | Synaptic vesicle glycoprotein 2c | 1.46 | 0.006 |
| **Genes related with biological process** |
| **GOTERM_BP_FAT embryonic organ development, 5 genes, p-value 0.024** |
| NM_001159487 | Rbp4 | Retinol binding protein 4, plasma | -2.16 | 0.027 |
Table II. Continued.

| Accession no. | Gene symbol | Gene name                                | FC    | q-value |
|---------------|-------------|------------------------------------------|-------|---------|
| NM_001307989  | Nr4a3       | Nuclear receptor subfamily 4, group A, member 3 | 1.01  | 0.010   |
| NM_139298     | Wnt9a       | Wingless-type MMTV integration site family, member 9A | -1.06 | 0.006   |
| NM_008937     | Prox1       | Prospero homeobox 1                       | 1.01  | 0.006   |
| NM_007729     | Coll1a1     | Collagen, type XI, α1                     | -1.08 | 0.020   |
|               |             | **GOTERM_BP_FAT positive regulation of transcription, 11 genes, p-value 5.21E-5** |       |         |
| NM_009538     | Plagl1      | Pleiomorphic adenoma gene-like 1          | 1.28  | 0.006   |
| NM_007913     | Egr1        | Early growth response 1                   | -1.55 | 0.006   |
| NM_010234     | Fox1        | FBJ osteosarcoma oncogene                 | -1.77 | 0.006   |
| NM_007225     | Hda4        | Histone deacetylase 4                     | 1.16  | 0.010   |
| NM_001305671 | Glis3       | GLIS family zinc finger 3                 | 1.25  | 0.006   |
| NM_001136072 | Meis2       | Meis homeobox 2                           | -2.37 | 0.006   |
| NM_010444     | Nr4a1       | Nuclear receptor subfamily 4, group A, member 1 | -1.77 | 0.006   |
| NM_019740     | Fox03       | Forhead box 03                            | 1.20  | 0.006   |
| NM_001307989  | Nr4a3       | Nuclear receptor subfamily 4, group A, member 3 | 1.01  | 0.006   |
| NM_0111141    | Pou3f1      | POU domain, class 3, transcription factor 1 | -3.65 | 0.006   |
| NM_153553     | Npas4       | Neuronal PAS domain protein 4             | -2.04 | 0.006   |

Genes were grouped into 6 functional categories: transcription activator activity, synapse, extracellular region, cell junction, embryonic organ development and positive regulation of transcription. Note that some genes were included in several categories. Gene function was attributed using DAVID bioinformatics database for clustering by functional annotation, and the number of genes and p-value of each biological function were included. FC represents the fold change between gene expressions of MPTP-exposed mice vs. saline-infused animals. DG, dentate gyrus; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Figure 5. Gene Ontology (GO) analysis, including cellular component (yellow), molecular function (blue) and biological process (red) of transcriptomic changes in the (A) subventricular zone (SVZ) and (B) dentate gyrus (DG) 3 weeks after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration. The analysis was performed using the annotation tool of the David bioinformatics database. GO pathways with >3 genes were considered significant if fold enrichment was ≥2-fold and the p-value <0.05. The vertical and horizontal axes were the GO terms and the logarithm of p-values, respectively. Importantly, some functions observed in the SVZ after MPTP intoxication were enhanced (e.g., positive regulation of transcription, transmission of nerve impulse, and myelination), while others were inversely affected (e.g., cell adhesion). In the DG, those functions with considerable activation were identified, including cell junction, synapse and fatty acid transport. Nevertheless, transcription activator activity, mitogen-activated protein (MAP) kinase phosphatase activity, extracellular region, and positive regulation of transcription were significantly downregulated.
and Nr4a3 encode orphan nuclear receptors that function as transcription factors (23). Nr4a1 has been linked to synaptic remodeling, behavioral changes, and dopaminergic loss after administrating MPTP in mice (27). The possible therapeutic role for Nr4a1 has been manifested since neural damage was rescued by Nr4a1 overexpression that decreased cell apoptotic rates (29) and was essential for neuronal differentiation (30).

In our study, genes involved in the MAPK pathway (Fos and Nr4a1) were significantly upregulated in the SVZ 3 weeks after MPTP administration. There are three major groups of MAPKs: i) ERK which is mainly activated by mitogenic stimuli, such as growth factors and hormones; ii) c-Jun N-terminal kinase (JNK) and p38 which are predominantly activated by stress stimuli, such as oxidative stress and inflammatory cytokines; and iii) ERK5 which is activated by both stress stimuli as well as growth factors (9,31). Notably, our results displayed that since the enhanced transcription of Fos was accompanied by Nr4a1, MPTP may selectively activate the ERK and ERK5 cascades in the SVZ at later stage, which may lead to the biological outcomes of cell proliferation and differentiation. Secondly, Slc17a7 and Egr2 genes may be involved in the function of glutamatergic synapse and myelination, respectively. Slc17a7 encodes the protein of vesicular glutamate transporter 1 (Vglut1) and functions in glutamate transport (32). Sconce et al suggested that the alleviation of motor deficits in mice exposed to MPTP was attributed to the recovery of extracellular Vglut1 and glutamatergic synapse (33). Others have identified a contribution of Vglut1 to glutamate release which could promote neuroblast migration and neurogenesis (34). In addition to neurotransmitter transporter, myelination that occurs primarily post-natally is essential for the efficient transmission of nerve impulses. Egr2 activates several genes that are involved in the formation and maintenance of myelin at early stage of myelination (35). Recent studies have provided evidence that oligodendrocyte progenitor cells in the SVZ migrate following exposure to stimuli and form glutamatergic synapse during the early stage of myelination process (35,36). Hence, the fact that the expression of Slc17a7 and Egr2 was time-dependent has led us to speculate that neurogenesis, including synaptic formation may be initially inhibited and further improved to partially rescue the dysfunctional dopaminergic system in our parkinsonian mice. Future studies shall attempt to reveal the mechanisms underlying the temporal profiles of gene expression.
Genes related to neurogenesis in the DG. Contrary to the expression profiles in the SVZ, the biological function of positive regulation of transcription in the DG was negatively affected by MPTP. In support of this hypothesis, the upregulation of histone deacetylase 4 (Hdac4) and the downregulation of Fos and Nr4a1 were observed and annotated to this function. In fact, Hdac4 encodes a protein to repress transcription, and the high expression of Hdac4 in granule cells of the DG is associated with neurodegeneration (37). Furthermore, these changes can impact several major targets of the MAPK pathway. Specifically, the ERK and ERK5 cascades may be inactivated by MPTP at a later stage as the downstream transcription factors, Fos and Nr4a1, were significantly downregulated after DA depletion. Indeed, the loss of the ERK cascade results in the depletion of neural progenitors, impairing granule cell neurogenesis in the DG (9,38). Jiang et al demonstrated that the inhibition of MAPK/ERK signaling aggravated hippocampal neuronal apoptosis, decreased neurogenesis and impaired cognitive performances (39). Thus, our results support the previous findings that neurogenesis in the SGZ of the DG decreased accompanying dopaminergic denervation after MPTP exposure (2,38). However, we identified significant decreases in the levels of Dusp1, as well as Dusp6, which were MAPK phosphatases and negative feedback regulators of ERK cascade (9,40). Consequently, by the MPTP-induced downregulation of Dusp1 and Dusp6, the inactivation of ERK could be reduced, leading to the compensatory reactions to the DA depletion.

In addition to the regulation of transcription, exposure to MPTP also affected genes mediating extracellular region remodeling, and cell junction, which may impact neural plasticity via cell migration or neurite outgrowth. We identified significant decreases in the expression of insulin-like growth factor 2 (Igf2), insulin-like growth factor binding protein 4 (Igfbp4), prostaglandin D2 synthase (Ptgds) and nephroblastoma overexpressed (Nov) which could be annotated to the extracellular region. Currently, it is well accepted that Igf2 encodes a member of the insulin-like growth factor family of proteins that can facilitate efficient signal transduction from extracellular region into the cell and promote growth and development (11,31). It also acts as a physiological amplifier of glucose-mediated insulin secretion (11,13), indicating a metabolic function. Moreover, the gene of Igfbp4 encodes the
IGF-binding proteins that have been shown to stimulate the growth promoting effects of the IGFs on cell culture (11,12). On the one hand, the MPTP-mediated downregulation of Igf2 and Igfbp4 may inhibit signal transduction, causing cell growth dysfunction. On the other hand, due to the insufficient secretion of insulin, an increase in fatty acid metabolism may begin, which was confirmed by our GO analysis. Shin et al. found that quiescent NSCs in the DG maintained an active fatty acid metabolism which began to wane when these cells were activated (13). Our findings of active biological process of fatty acid transport may partially lead to the speculation that NSCs may be inactivated in the DG. Other downregulated genes related to extracellular region included collagen, type XI, α1 (Col11a1) (41) and decorin (Dcn) (42) that may have a negative impact on collagen metabolism and assembly after dopaminergic denervation. Apart from a negative effect on extracellular region remodeling, the considerable activation of cell junction and synapse were observed following exposure to MPTP, which suggested that there were some compensatory mechanisms in the DG to enable communication between neighboring cells and reduce stress. Overall, we demonstrated that exposure to MPTP may have the potential to inhibit the expression of genes encoding proteins that could regulate extracellular matrix structure to prevent cell migration within the DG.

In conclusion, our findings demonstrated that exposure to MPTP affects gene expression in the SVZ and DG. The time-dependent expression profiles in the SVZ have led us to speculate that neurogenesis may be initially inhibited and further improved in our mice with PD. Nevertheless, expression analysis has shown the dysfunction of cell proliferation and migration in the DG. Several deregulated genes that participate in the glucose and lipid metabolisms may result in metabolic switch in these two regions. It is worth emphasizing that the MAPK signaling pathway has been activated in the SVZ, while negatively regulated in the DG after MPTP administration. Future studies shall attempt to reveal the mechanisms underlying neuroplasticity in the SVZ and SGZ using single-cell sequencing to avoid cellular heterogeneity within mixed cell populations.

Acknowledgements

This study was supported by the National High Technology Research and Development Program of China (2013AA020106 and 2014AA020513), National Basic Research Program of China (2014CB541603), and National Natural Science Foundation of China (81200916).

References

1. Ming GL and Song H: Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 70: 687-702, 2011.
2. Höglinger GU, Rick P, Muriel MP, Duyckaerts C, Oertel WH, Cahil I and Hirsch EC: Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7: 726-735, 2004.
3. Ohtani N, Goto T, Waeber C and Bhide PG: Dopamine modulates cell cycle in the lateral ganglionic eminence. J Neurosci 21: 2840-2850, 2003.
4. van den Berge SA, van Strien ME, Korecka JA, Dijkstra AA, Slijis JA, Kooijman J, Eggers R, De Filippis L, Vescovi AL, Verhaagen J, et al.: The proliferative capacity of the subventricular zone is maintained in the parkinsonian brain. Brain 134: 3249-3263, 2011.
5. Marxreiter F, Regensburger M and Winkler J: Adult neurogenesis in Parkinson’s disease. Cell Mol Life Sci 70: 459-473, 2013.
6. Hørkko PM, Faull RL and Connor B: Increased progenitor cell proliferation and astrogensis in the partial progressive 6-hydroxydopamine model of Parkinson’s disease. Neuroscience 151: 1142-1153, 2008.
7. Winner B, Geyer M, Couillard-Despres S, Aigner R, Bogdahn U, Aigner L, Kuhn G and Winkler J: Striatal dedifferentiation increases dopaminergic neurogenesis in the adult olfactory bulb. Exp Neurol 197: 113-121, 2006.
8. Horgusluoglu E, Nudelman K, Nho K and Saykin AJ: Adult neurogenesis and neurodegenerative diseases: a systems biology perspective. Am J Med Genet B Neuropsychiatr Genet 174: 93-112, 2017.
9. Faigle R and Song H: Signaling mechanisms regulating adult neural stem cells and neurogenesis. Biochim Biophys Acta 1830: 2435-2448, 2013.
10. Llorrens-Bobadilla E, Zhao S, Baser A, Saiz-Castro G, Zwollo K and Martin-Villalba A: Single-cell transcriptomics reveals a population of dormant neural stem cells that become activated upon brain injury. Cell Stem Cell 17: 329-340, 2015.
11. Agis-Balboa RC, Arcos-Diaz D, Wittnam J, Govindarajan N, Blom K, Burkhards, S, Haladynia U, Agbemenyah HY, Zovolias A, Salinas-Riester G, et al.: A hippocampal insulin-growth factor 2 pathway regulates the extinction of fear memories. EMBO J 30: 4071-4083, 2011.
12. Zhou R, Diehl D, Hoeflich A, Lahm H and Wolf E: IGF-binding protein-4: biochemical characteristics and functional consequences. J Endocrinol 178: 177-193, 2003.
13. Thies K, Berg DA, Zhu Y, Shin JY, Song J, Bonaguidi MA, Enikolopov G, Nauen DW, Christian KM, Ming GL, et al.: Single-cell RNA-seq with waterfall reveals molecular cascades underlying adult neurogenesis. Cell Stem Cell 17: 360-372, 2015.
14. Zuo FX, Bao XJ, Sun XC, Wu J, Bai QR, Chen G, Li XY, Zhou QY, Yang YF, Shen Q, et al.: Transplantation of human neural stem cells in a parkinsonian model exerts neuroprotection via regulation of the host microenvironment. Int J Mol Sci 16: 26473-26492, 2015.
15. Jackson-Lewis V and Przedborski S: Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc 2: 141-151, 2007.
16. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ and Lee VM: Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34: 521-533, 2002.
17. Trappnell C, Roberts A, Goff L, Pertega G, Kim D, Kelley DR, Pimentel M, Salzberg SL, Rinn JL and Pachter L: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7: 562-578, 2012.
18. Ye J, Fang L, Zheng L, Zhang Y, Chen J, Zhang Z, Wang J, Li R, Bolund L, et al.: WEGO: a web tool for plotting GO annotations. Nucleic Acids Res 34 (Web server): W293-W297, 2006.
19. Kolobova E, Tuganova A, Boulatnikov I and Popov KM: Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem J 358: 69-77, 2001.
20. Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, Ratan RR and Andersen JK: Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disorder. J Biol Chem 284: 29065-29076, 2009.
21. Daniele S, Lecca D, Trincavelli ML, Ciampi O, Abbracchio MP and Martini C: Regulation of PC12 cell survival and differentiation by the new P2Y-like receptor GPR17. Cell Signal 22: 907-916, 2010.
22. Champeau-Beaufel F, Malerci M, Alcacer C, Tahiri H, Carpentier W, Wang C, During M, Xu D, Worley PF, Girault JA, et al.: Gene expression analyses identify Narp contribution in the development of L-DOPA-induced dyskinnesia. J Neurosci 35: 106-111, 2015.
23. Süderstien E, Feyder M, Lerdrup M, Gomes AL, Kryh H, Spigolon G, Caboche J, Fisone G and Hansen K: Dopamine signaling leads to loss of Polycym repression and aberrant gene activation in experimental parkinsonism. PLoS Genet 10: e1004574, 2014.
24. Gao S, Jin UH, Morpurgo B, Abudayeh Y, Singh M and Tjalkens RB: Nuclear receptor 4A (NR4A) family - orphans no more. J Steroid Biochem Mol Biol 157: 48-50, 2016.
25. Björklund A and Dunnett SB: Dopamine neuron systems in the brain: an update. Trends Neurosci 30: 194-202, 2007.

26. Baker SA, Baker KA and Hagg T: Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone. Eur J Neurosci 20: 575-579, 2004.

27. Eells JB, Wilcots J, Sisk S and Guo-Ross SX: NR4A gene expression is dynamically regulated in the ventral tegmental area dopamine neurons and is related to expression of dopamine neurotransmitter genes. J Mol Neurosci 46: 545-553, 2012.

28. Velazquez FN, Prucca CG, Etienne O, D’Astolfo DS, Silvestre DC, Boussin FD and Caputto BL: Brain development is impaired in c-fos -/- mice. Oncotarget 6: 16883-16901, 2015.

29. Xiao G, Sun T, Songming C and Cao Y: NR4A1 enhances neural survival following oxygen and glucose deprivation: an in vitro study. J Neurol Sci 330: 78-84, 2013.

30. Tomioka T, Maruoka H, Kawa H, Yamazoe R, Fujiki D, Shimoke K and Ikeuchi T: The histone deacetylase inhibitor trichostatin A induces neurite outgrowth in PC12 cells via the epigenetically regulated expression of the nur77 gene. Neurosci Res 88: 39-48, 2014.

31. Yang SH, Sharrocks AD and Whitmarsh AJ: Transcriptional regulation by the MAP kinase signaling cascades. Gene 320: 3-21, 2003.

32. Guo Z, Zhang L, Wu Z, Chen Y, Wang F and Chen G: In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer's disease model. Cell Stem Cell 14: 188-202, 2014.

33. Scone MD, Churchill MJ, Greene RE and Meshul CK: Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease. Neuroscience 299: 156-174, 2015.

34. Sánchez-Mendoza E, Burguete MC, Castelló-Ruiz M, González MP, Roncero C, Salom JB, Arce C, Cañadas S, Torregrosa G, Alborch E, et al: Transient focal cerebral ischemia significantly alters not only EAATs but also VGLUTs expression in rats: relevance of changes in reactive astroglia. J Neurochem 113: 1343-1355, 2010.

35. Etxeberria A, Mangin JM, Aguirre A and Gallo V: Adult-born SVZ progenitors receive transient synapses during remyelination in corpus callosum. Nat Neurosci 13: 287-289, 2010.

36. Aguirre A, Dupree JL, Mangin JM and Gallo V: A functional track for EGFR signaling in myelination and remyelination. Nat Neurosci 10: 990-1002, 2007.

37. Whitehouse A, Doherty K, Yeh HH, Robinson AC, Rollinson S, Pickering-Brown S, Snowden J, Thompson JC, Davidson YS and Mann DM: Histone deacetylases (HDACs) in frontotemporal lobar degeneration. Neuropathol Appl Neurobiol 41: 245-257, 2015.

38. Vithayathil J, Pucilowska J, Goodnough LH, Atti RP and Landreth GE: Dentate gyrus development requires ERK activity to maintain progenitor population and MAPK pathway feedback regulation. J Neurosci 35: 6836-6848, 2015.

39. Jiang P, Zhu T, Xia Z, Gao F, Gu W, Chen X, Yuan T and Yu H: Inhibition of MAPK/ERK signaling blocks hippocampal neurogenesis and impairs cognitive performance in prenatally infected neonatal rats. Eur Arch Psychiatry Clin Neurosci 265: 497-509, 2015.

40. Banzhaf-Strathmann J, Benito E, May S, Arzberger T, Tahirovic S, Kretzschmar H, Fischer A and Edbauer D: MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease. EMBO J 33: 1667-1680, 2014.

41. Majava M, Hoornaert KP, Bartholdi B, Bourna MC, Bouman K, Carrera M, Devriendt K, Hurst J, Kittos G, Niedrist D, et al: A report on 10 new patients with heterozygous mutations in the COL11A1 gene and a review of genotype-phenotype correlations in type XI collagenopathies. Am J Med Genet A 143A: 258-264, 2007.

42. Buraschi S, Neill T, Goyal A, Poluzzi C, Smythies J, Owens RT, Schaefer L, Torres A and Iozzo RV: Decorin causes autophagy in endothelial cells via Peg3. Proc Natl Acad Sci USA 110: E2582-E2591, 2013.